3% vs. 25.2%, 52.2% vs. 41.5%, and 58.5% vs. AZD6244 ic50 47.2%,

respectively) (Figure 2b). Furthermore, we evaluated the combined effect of 5-hmC and IDH2 expression. We found that the 1-, 3-, and 5-year OS rates in the 5-hmC Low/IDH2 Low patients were 64.6%, 43.1%, and 43.1%, respectively, which were significantly lower than those in the 5-hmC High/IDH2 High patients (98.5%, 89.2%, and 86.2%, respectively) (Figure 2a). The cumulative recurrence rates in the 5-hmC Low/IDH2 Low patients were 52.3%, 63.1% and 66.2%, respectively, which were significantly higher than those in the 5-hmC High/IDH2 High patients (15.4%, 26.2% and 30.8%, respectively) (Figure 2b). Figure 2 5-hmC and IDH2 expression and prognostic value in HCC Tucidinostat molecular weight tissue (training cohort, N = 318). Kaplan-Meier curves depiciting OS (a) and TTR (b) for 5-hmC expression, IDH2 expression, and combined 5-hmC/IDH2 expression. I, 5-hmC High/IDH2 High; II, 5-hmC Low/IDH2

High; III, https://www.selleckchem.com/products/pnd-1186-vs-4718.html 5-hmC High/IDH2 Low; IV, 5-hmC Low/IDH2 Low. Univariate analysis revealed that 5-hmC (P <0.001 and P = 0.001), IDH2 (P <0.001 and P = 0.006), and 5-hmC/IDH2 combined (P <0.001 and P <0.001) were associated with OS and TTR. γ-GT, tumor number, tumor size, microvascular invasion, and TNM stage were predictors of OS and TTR. Moreover, AFP was only associated with OS, and liver cirrhosis was only associated with TTR (Table 2). Table 2 Summary of univariate and multivariate analyses of 5-hmC and IDH2 protein expression associated with survival and recurrence in the training cohort (N = 318) Factor OS TTR Multivariate Multivariate Univariate P Hazard

ratio 95% CI P† Univariate P Hazard ratio 95% CI P† Sex (female vs. male) 0.959     NA 0.083     NA Age, years (≤50 vs. >50) 0.772 mafosfamide     NA 0.597     NA HBsAg (negative vs. positive) 0.983     NA 0.491     NA AFP, ng/ml (≤20 vs. >20) 0.041 1.893 1.257–2.852 0.002 0.230     NA γ-GT, U/L (≤54 vs. >54) 0.006 1.619 1.118–2.343 0.011 0.003 1.547 1.138–2.102 0.005 Liver cirrhosis (no vs. yes) 0.077     NA 0.009 1.824 1.135–2.930 0.013 Tumor number (single vs. multiple) 0.003     NS 0.002 1.651 1.135–2.402 0.009 Tumor size, cm (≤5 vs. >5) 0.009     NS 0.041     NS Tumor encapsulation (complete vs. none) 0.261     NA 0.166     NA Microvascular invasion (no vs. yes) 0.003     NS 0.001 1.775 1.287–2.448 <0.001 Tumor differentiation (I-II vs. III-IV) 0.138     NA 0.053     NA TNM stage (I vs. II III) <0.001 2.048 1.412–2.971 <0.001 <0.001 1.649 1.134–2.397 0.009 5-hmC (low vs. high) <0.001 0.316 0.211–0.472 <0.001 0.001 0.462 0.335–0.636 <0.001 IDH2 (low vs. high) <0.001 0.405 0.275–0.594 <0.001 0.006 0.591 0.432–0.810 0.001 Combination of 5-hmC and IDH2 <0.001     <0.001 <0.001     <0.001 I versus II 0.002 3.987 1.890–8.413 <0.001 0.001 2.651 1.576–4.461 <0.001 I versus III 0.002 3.359 1.607–7.025 0.001 0.003 2.098 1.247–3.530 0.005 I versus IV <0.001 8.908 4.215–18.825 <0.001 <0.001 3.891 2.270–6.671 <0.